ACE2 and COVID-19: Indeed, there is currently no data and statistics evidencing a direct link between ACE2 activity and SARS-CoV-2 associated mortality or between ACE-I or angiotensin-receptor blockers (ARB) treatment and impaired outcome in COVID-19 [11–13].